These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32067834)

  • 1. Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis.
    Stolfo D; Albani S; Savarese G; Barbati G; Ramani F; Gigli M; Biondi F; Dal Ferro M; Zecchin M; Merlo M; Sinagra G
    Int J Cardiol; 2020 May; 307():75-81. PubMed ID: 32067834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors predisposing to the reprogramming of implantable cardioverter-defibrillators and the causes of changes in pharmacotherapy in patients with dilated cardiomyopathy for primary prevention of sudden cardiac death].
    Pudło J; Liszniański P; Senderek T; Lelakowska-Pieła M; Lelakowski J; Nowak J
    Pol Merkur Lekarski; 2015 Aug; 39(230):86-90. PubMed ID: 26319381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?".
    Zecchin M; Merlo M; Pivetta A; Barbati G; Lutman C; Gregori D; Serdoz LV; Bardari S; Magnani S; Di Lenarda A; Proclemer A; Sinagra G
    Am J Cardiol; 2012 Mar; 109(5):729-35. PubMed ID: 22176998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction.
    Merlo M; Gentile P; Artico J; Cannatà A; Paldino A; De Angelis G; Barbati G; Alonge M; Gigli M; Pinamonti B; Ramani F; Zecchin M; Pirozzi F; Stolfo D; Sinagra G
    J Cardiovasc Med (Hagerstown); 2019 May; 20(5):343-350. PubMed ID: 30921270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive markers for sudden cardiac death risk stratification in dilated cardiomyopathy.
    Pooranachandran V; Nicolson W; Vali Z; Li X; Ng GA
    Heart; 2022 Jun; 108(13):998-1004. PubMed ID: 34670824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
    Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of implantable cardioverter defibrillator on the prognosis of nonischemic dilated cardiomyopathy patients compared with standard medical treatments.
    Salehi Omran H; Naghashzadeh F; Irilouzadian R; Dolatshahi S; Hedayati Goudarzi MT; Salehi Omran MT
    Clin Cardiol; 2023 Jun; 46(6):674-679. PubMed ID: 37057368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late gadolinium enhancement and the risk of ventricular arrhythmias and sudden death in NYHA class I patients with non-ischaemic cardiomyopathy.
    Di Marco A; Brown P; Mateus G; Faga V; Nucifora G; Claver E; Viedma J; Galvan F; Bradley J; Dallaglio PD; de Frutos F; Miller CA; Comín-Colet J; Anguera I; Schmitt M
    Eur J Heart Fail; 2023 May; 25(5):740-750. PubMed ID: 36781200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk).
    Kayvanpour E; Sammani A; Sedaghat-Hamedani F; Lehmann DH; Broezel A; Koelemenoglu J; Chmielewski P; Curjol A; Socie P; Miersch T; Haas J; Gi WT; Richard P; Płoski R; Truszkowska G; Baas AF; Foss-Nieradko B; Michalak E; Stępień-Wojno M; Zakrzewska-Koperska J; Śpiewak M; Zieliński T; Villard E; Te Riele ASJM; Katus HA; Frey N; Bilińska ZT; Charron P; Asselbergs FW; Meder B
    Int J Cardiol; 2021 Sep; 339():75-82. PubMed ID: 34245791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
    Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction.
    van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP
    Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive parameters of occurrence of adequate interventions in patients with implanted cardioverter-defibrillators with or without resynchronisation therapy in primary prevention of sudden cardiac death in dilated cardiomyopathy].
    Lelakowski J; Rydlewska A; Lelakowska M; Pudło J; Piekarz J
    Pol Merkur Lekarski; 2017 Feb; 42(248):65-70. PubMed ID: 28258679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study.
    Salerno-Uriarte JA; De Ferrari GM; Klersy C; Pedretti RF; Tritto M; Sallusti L; Libero L; Pettinati G; Molon G; Curnis A; Occhetta E; Morandi F; Ferrero P; Accardi F;
    J Am Coll Cardiol; 2007 Nov; 50(19):1896-904. PubMed ID: 17980258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction.
    Muhammed A; Abdelazeem M; Elewa MG; Sharief M; Ammar A
    Heart Fail Rev; 2023 Jan; 28(1):229-240. PubMed ID: 35587303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.